CSL Limited (CSLLY)
USD 81.65
(0.89%)
USD 81.65
(0.89%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | 2.64 Billion USD | -20.81% |
| 2023 | 2.19 Billion USD | -2.69% |
| 2022 | 2.25 Billion USD | -5.07% |
| 2021 | 2.37 Billion AUD | 12.96% |
| 2020 | 2.1 Billion AUD | 9.58% |
| 2019 | 1.91 Billion AUD | 10.98% |
| 2018 | 1.72 Billion AUD | 29.27% |
| 2017 | 1.33 Billion AUD | 7.65% |
| 2016 | 1.24 Billion AUD | -9.91% |
| 2015 | 1.37 Billion AUD | 5.51% |
| 2014 | 1.3 Billion AUD | 7.46% |
| 2013 | 1.21 Billion AUD | 20.95% |
| 2012 | 1 Billion AUD | 0.03% |
| 2011 | 1 Billion AUD | 12.34% |
| 2010 | 894.82 Million AUD | -3.24% |
| 2009 | 924.82 Million AUD | 37.74% |
| 2008 | 671.44 Million AUD | 46.79% |
| 2007 | 457.42 Million AUD | 425.26% |
| 2006 | 87.08 Million AUD | -79.1% |
| 2005 | 416.71 Million AUD | 171.39% |
| 2004 | 153.55 Million AUD | 223.6% |
| 2003 | 47.45 Million AUD | -31.92% |
| 2002 | 69.7 Million AUD | 74.58% |
| 2001 | 39.92 Million AUD | 22.92% |
| 2000 | 32.48 Million AUD | 2.69% |
| 1999 | 31.62 Million AUD | 13.59% |
| 1998 | 27.84 Million AUD | 5.11% |
| 1997 | 26.49 Million AUD | 0.0% |
| 1996 | - AUD | 100.0% |
| 1995 | -4971.41 AUD | -161.85% |
| 1994 | 8037.70 AUD | -99.91% |
| 1993 | 9.24 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q4 | 737.77 Million USD | 0.0% |
| 2024 FY | 2.64 Billion USD | 20.42% |
| 2024 Q1 | 1.47 Billion USD | 145.94% |
| 2024 Q2 | 1.9 Billion USD | 0.0% |
| 2023 Q1 | 1.26 Billion USD | 154.35% |
| 2023 FY | 2.19 Billion USD | -2.69% |
| 2023 Q4 | 601.2 Million USD | 40.83% |
| 2023 Q3 | 426.9 Million USD | -73.97% |
| 2023 Q2 | 1.64 Billion USD | 29.27% |
| 2022 Q4 | 498.82 Million USD | 50.92% |
| 2022 Q2 | 1.76 Billion USD | 44.53% |
| 2022 FY | 2.25 Billion USD | -5.07% |
| 2022 Q3 | 330.53 Million USD | -81.22% |
| 2022 Q1 | 1.21 Billion USD | 122.93% |
| 2021 Q4 | 546.33 Million USD | 46.9% |
| 2021 Q3 | 371.91 Million USD | -79.45% |
| 2021 Q1 | 1.26 Billion USD | 44.87% |
| 2021 Q2 | 1.81 Billion USD | 43.18% |
| 2021 FY | 2.37 Billion AUD | 12.96% |
| 2020 Q4 | 872.56 Million USD | 25.59% |
| 2020 FY | 2.1 Billion AUD | 9.58% |
| 2020 Q2 | 1.24 Billion USD | 34.99% |
| 2020 Q1 | 924.51 Million USD | 20.41% |
| 2020 Q3 | 694.75 Million USD | -44.33% |
| 2019 Q3 | 533.78 Million USD | -35.21% |
| 2019 FY | 1.91 Billion AUD | 10.98% |
| 2019 Q1 | 802.97 Million USD | 84.97% |
| 2019 Q4 | 767.78 Million AUD | 43.84% |
| 2019 Q2 | 823.92 Million USD | 2.61% |
| 2018 Q2 | 696.04 Million USD | 0.5% |
| 2018 Q3 | 418.23 Million USD | -39.91% |
| 2018 Q4 | 434.1 Million AUD | 3.8% |
| 2018 FY | 1.72 Billion AUD | 29.27% |
| 2018 Q1 | 692.57 Million USD | 100.15% |
| 2017 Q2 | 558.13 Million USD | 6.07% |
| 2017 Q1 | 526.17 Million USD | 49.72% |
| 2017 FY | 1.33 Billion AUD | 7.65% |
| 2017 Q4 | 346.02 Million AUD | -0.6% |
| 2017 Q3 | 348.1 Million USD | -37.63% |
| 2016 Q3 | 340.64 Million USD | -30.98% |
| 2016 Q4 | 351.42 Million AUD | 3.17% |
| 2016 FY | 1.24 Billion AUD | -9.91% |
| 2016 Q2 | 493.51 Million USD | -3.47% |
| 2016 Q1 | 511.22 Million USD | 14.57% |
| 2015 Q3 | 450.24 Million USD | 6.45% |
| 2015 Q2 | 422.95 Million USD | 6.9% |
| 2015 Q1 | 395.64 Million USD | 12.85% |
| 2015 FY | 1.37 Billion AUD | 5.51% |
| 2015 Q4 | 446.19 Million AUD | -0.9% |
| 2014 Q3 | 356.62 Million USD | -1.21% |
| 2014 FY | 1.3 Billion AUD | 7.46% |
| 2014 Q1 | 345.4 Million USD | 7.77% |
| 2014 Q4 | 350.6 Million AUD | -1.69% |
| 2014 Q2 | 360.99 Million USD | 4.51% |
| 2013 FY | 1.21 Billion AUD | 20.95% |
| 2013 Q2 | 300.79 Million USD | -0.06% |
| 2013 Q4 | 320.49 Million AUD | 13.7% |
| 2013 Q1 | 300.97 Million USD | 0.0% |
| 2013 Q3 | 281.88 Million USD | -6.29% |
| 2012 FY | 1 Billion AUD | 0.03% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 FY | 1 Billion AUD | 12.34% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | 894.82 Million AUD | -3.24% |
| 2010 Q4 | - AUD | 0.0% |
| 2009 FY | 924.82 Million AUD | 37.74% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 FY | 671.44 Million AUD | 46.79% |
| 2007 FY | 457.42 Million AUD | 425.26% |
| 2007 Q4 | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2006 FY | 87.08 Million AUD | -79.1% |
| 2005 FY | 416.71 Million AUD | 171.39% |
| 2005 Q4 | - AUD | 0.0% |
| 2004 FY | 153.55 Million AUD | 223.6% |
| 2004 Q4 | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 FY | 47.45 Million AUD | -31.92% |
| 2002 Q4 | - AUD | 0.0% |
| 2002 FY | 69.7 Million AUD | 74.58% |
| 2001 FY | 39.92 Million AUD | 22.92% |
| 2001 Q4 | - AUD | 0.0% |
| 2000 FY | 32.48 Million AUD | 2.69% |
| 2000 Q4 | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1999 FY | 31.62 Million AUD | 13.59% |
| 1998 FY | 27.84 Million AUD | 5.11% |
| 1998 Q4 | - AUD | 0.0% |
| 1997 FY | 26.49 Million AUD | 0.0% |
| 1997 Q4 | - AUD | 0.0% |
| 1996 FY | - AUD | 100.0% |
| 1995 FY | -4971.41 AUD | -161.85% |
| 1994 FY | 8037.70 AUD | -99.91% |
| 1993 FY | 9.24 Million AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 197938.75% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 37935.63% |
| Evofem Biosciences, Inc. | 52.97 Million USD | -4886.882% |
| Nascent Biotech, Inc. | -2.08 Million USD | 126651.841% |
| Rebus Holdings, Inc. | -1.02 Million USD | 259119.608% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | -3956.32% |
| Qrons Inc. | -789.34 Thousand USD | 334807.043% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 417868.937% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 4320.515% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 635992.548% |
| Skye Bioscience, Inc. | -37.64 Million USD | 7118.237% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 3624.405% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 40275.721% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 966442.602% |
| SQZ Biotechnologies Company | -79.46 Million USD | 3424.776% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 91443.019% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 145222.734% |
| Mesoblast Limited | -87.95 Million USD | 3103.775% |
| Marizyme, Inc. | -65.34 Million USD | 4143.037% |
| Genus plc | 7.9 Million USD | -33343.038% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 24356.912% |
| Pharming Group N.V. | -10.54 Million USD | 25147.402% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 121861.589% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 71308.447% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 29973.36% |
| ContraFect Corporation | -65.15 Million USD | 4155.07% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 54172.164% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 153041.755% |
| IMV Inc. | -36.48 Million USD | 7341.194% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 32880.45% |
| MultiCell Technologies, Inc. | -380.07 USD | 695135206.691% |
| ONE Bio Corp. | 8.67 Million USD | -30349.673% |
| Accustem Sciences Inc. | -3.74 Million USD | 70620.676% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 5211.042% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 208602.021% |
| Q BioMed Inc. | -2.05 Million USD | 128846.602% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 70874.176% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 111067.839% |
| Biomind Labs Inc. | -1.21 Million USD | 217670.507% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 4523.579% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 85277.228% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 33529.95% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 135639.38% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 17641659.829% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 16746.249% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 45516.625% |
| GB Sciences, Inc. | -1.36 Million USD | 194125.455% |
| Alpha Cognition Inc. | -13.77 Million USD | 19283.062% |
| HST Global, Inc. | -146.21 Thousand USD | 1807089.946% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 150660.956% |
| Halberd Corporation | -79.67 Thousand USD | 3316029.515% |
| Enzolytics Inc. | -2.17 Million USD | 121469.035% |
| Agentix Corp. | -1.37 Million USD | 192355.774% |
| Resverlogix Corp. | -3.61 Million USD | 73285.596% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 83406.111% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -295.05 Million USD | 995.432% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -2695818.367% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -38053.861% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 66598.985% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 87406.085% |
| AVAX Technologies, Inc. | -6.41 Million USD | 41293.405% |
| Zenith Capital Corp. | -10.59 Million USD | 25033.937% |
| Genscript Biotech Corporation | -95.47 Million USD | 2867.159% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 11367452.207% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 63825.055% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 4371333.182% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 131863.016% |
| Kadimastem Ltd | -3.3 Million USD | 79981.526% |
| Helix BioMedix, Inc. | -1.05 Million USD | 250275.89% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 69280.414% |
| BioStem Technologies, Inc. | -8.48 Million USD | 31244.701% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 598692.108% |
| LadRx Corporation | 400.44 Thousand USD | -659669.305% |
| Cell Source, Inc. | -5.32 Million USD | 49750.343% |
| Regen BioPharma, Inc. | 1.02 Million USD | -258031.837% |
| Regen BioPharma, Inc. | 1.02 Million USD | -258031.837% |
| NovAccess Global Inc. | -4.76 Million USD | 55497.283% |
| Affymax, Inc. | -14.42 Million USD | 18416.694% |
| Itoco Inc. | -1.86 Million USD | 141459.394% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 59570.55% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 158398.382% |
| Mobile Lads Corp. | -2.26 Million USD | 116832.618% |
| CytoDyn Inc. | -49.84 Million USD | 5400.857% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 3343007.393% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 1158226.833% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 280707.395% |
| SYBLEU INC | -180.3 Thousand USD | 1465403.044% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 163920.883% |
| International Stem Cell Corporation | -131 Thousand USD | 2016893.893% |
| Bioxytran, Inc. | -4.28 Million USD | 61828.943% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 4868171.934% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 104516.683% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 5595.923% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 125076.348% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 338433.203% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 83496.465% |
| Neutra Corp. | -233.46 Thousand USD | 1131747.142% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 13120.551% |
| PureTech Health plc | -65.69 Million USD | 4121.493% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 12523.273% |
| IXICO plc | -1.17 Million USD | 224378.438% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 26714.284% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 4724.702% |
| CSL Limited | 2.64 Billion USD | 0.0% |
| Cellectis S.A. | -103.17 Million USD | 2660.726% |